About: Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?
Creator	Alam, Mahboob Atar, Dan Birnbaum, Yochai French, John Hasdai, David Jneid, Hani Kaski, Juan Levine, Glenn Uretsky, Barry
Source	Medline; PMC
abstract	The pivotal studies that led to the recommendations for emergent reperfusion therapy for ST-elevation myocardial infarction (STEMI) were conducted for the most part over 25 years ago. At that time, contemporary standard treatments including aspirin, statin, and even anticoagulation were not commonly used. The 2013 American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) guidelines and the 2017 European Society of Cardiology guidelines give a class I recommendation (with the level of evidence A) for primary percutaneous coronary intervention (pPCI) in patients with STEMI and ischemic symptoms of less than 12 h. However, if the patient presents to a hospital without pPCI capacity, and it is anticipated that pPCI cannot be performed within 120 min of first medical contact, fibrinolytic therapy is indicated (if there are no contraindications) (class I indication, level of evidence A). Our review of the pertinent literature shows that the current recommendation for inferior STEMI is based on the level of evidence lower than A. We can consider level B even C, supporting the recommendation for fibrinolytic therapy if pPCI is not available for inferior STEMI.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1007/s10557-020-07039-0
bibo:pmid	32671603
has license	no-cc
sha1sum (hex)	71a2585672ac1c7454ee1d5c38950a07c4fe255f
schema:url	https://doi.org/10.1007/s10557-020-07039-0
resource representing a document's title	Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?
has PubMed Central identifier	PMC7360897
has PubMed identifier	32671603
schema:publication	Cardiovasc Drugs Ther
resource representing a document's body	covid:71a2585672ac1c7454ee1d5c38950a07c4fe255f#body_text
is schema:about of	named entity 'hospital' named entity 'STEMI' named entity 'literature' named entity 'infarction' named entity 'patient' named entity '25 years' named entity 'emergent' named entity 'anticoagulation' named entity 'evidence' named entity 'fibrinolytic therapy' named entity 'Our' named entity 'fibrinolytic therapy' named entity 'STEMI' named entity 'contact' named entity 'Current' named entity 'anticoagulation' named entity 'fibrinolytic therapy' named entity 'ACCF' named entity 'Primary Percutaneous Coronary Intervention' named entity 'European Society of Cardiology' named entity 'primary percutaneous coronary intervention' named entity 'aspirin' named entity 'ST-Elevation' named entity 'ischemic' named entity 'fibrinolytic therapy' named entity 'AHA' named entity 'presents' named entity 'ST-elevation' named entity 'CURRENT' named entity 'STEMI' named entity 'American Heart Association' named entity 'myocardial infarction' named entity 'reperfusion therapy' named entity 'American College of Cardiology Foundation' named entity 'STEMI' named entity 'CURRENT' named entity 'PRIMARY PERCUTANEOUS CORONARY INTERVENTION' named entity 'statin' named entity 'STEMI' named entity 'STEMI' named entity 'Myocardial Infarction' covid:arg/71a2585672ac1c7454ee1d5c38950a07c4fe255f named entity 'CONSIDER' named entity 'CAPACITY' named entity 'INDICATION' named entity 'STANDARD' named entity 'AMERICAN HEART ASSOCIATION' named entity 'INCLUDING' named entity 'TREATMENTS' named entity 'TIME' named entity 'CONTACT' named entity 'ADHERE TO' named entity 'American Heart Association (AHA)' named entity 'pivotal' named entity 'ischemic' named entity 'Society' named entity 'anticipated' named entity 'patients' named entity 'Cardiology' named entity 'pertinent' named entity 'evidence' named entity 'Foundation' named entity 'commonly' named entity 'indication' named entity 'percutaneous coronary intervention' named entity 'Myocardial Infarction' named entity 'LESS THAN' named entity 'ASPIRIN' named entity 'FIBRINOLYTIC THERAPY' named entity 'LEVEL OF EVIDENCE' named entity 'PATIENT' named entity 'PATIENTS' named entity 'evidence'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software